Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis

Book review

Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 770 · see citing works

Cyclic nucleotide phosphodiesterases

Essayan, D. M. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.119555 · Cited by 503 · see citing works

The Molecular Biology of Cyclic Nucleotide Phosphodiesterases

Conti, M., & Jin, S.-L. C. (1999) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60718-7 · Cited by 436 · see citing works

Distribution of α2-adrenergic receptor subtype gene expression in rat brain

Scheinin, M., Lomasney, J. W., Hayden‐Hixson, D. M., Schambra, U. B., Caron, M. G., Lefkowitz, R. J., & Fremeau, R. T. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90386-7 · Cited by 430 · see citing works

Anesthesia and Analgesia in Laboratory Animals

(1997) · Elsevier eBooks · doi:10.1016/b978-0-12-417570-9.x5000-4 · Cited by 422 · see citing works

A Hypnotic Response to Dexmedetomidine, an α2 Agonist, Is Mediated in the Locus Coerüleus in Rats

Corréa-Sales, C., Rabin, B. C., & Maze, M. (1992) · Anesthesiology · doi:10.1097/00000542-199206000-00013 · Cited by 403 · see citing works

Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses

Jin, S.-L. C., & Conti, M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122041599 · Cited by 368 · see citing works

Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A

Fawcett, L., Baxendale, R. W., Stacey, P., McGrouther, C., Harrow, I., Soderling, S. H., Hetman, J., Beavo, J. A., & Phillips, S. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3702 · Cited by 359 · see citing works

Atomic Structure of PDE4: Insights into Phosphodiesterase Mechanism and Specificity

Xu, R. X., Hassell, A. M., Vanderwall, D. E., Lambert, M. H., Holmes, W. D., Luther, M., Rocque, W. J., Milburn, M. V., Zhao, Y., Ke, H., et al. (2000) · Science · doi:10.1126/science.288.5472.1822 · Cited by 336 · see citing works

Long PDE4 cAMP specific phosphodiesterases are activated by protein kinase A‐mediated phosphorylation of a single serine residue in Upstream Conserved Region 1 (UCR1)

MacKenzie, S. J., Baillie, G. S., McPhee, I., MacKenzie, C., SEAMONS, R. A., McSorley, T., Millen, J. E., Beard, M., Heeke, G. V., & Houslay, M. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704743 · Cited by 261 · see citing works

Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice

Jin, S.-L. C., Richard, F. J., Kuo, W.-P., D’Ercole, A. J., & Conti, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.11998 · Cited by 232 · see citing works

Current Therapeutic Research

(2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00139-5 · Cited by 198 · see citing works

The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation.

Sette, C., Iona, S., & Conti, M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37100-4 · Cited by 181 · see citing works

ArifloTM(SB 207499), a Second Generation Phosphodiesterase 4 Inhibitor for the Treatment of Asthma and COPD: from Concept to Clinic

Torphy, T. J., Barnette, M. S., Underwood, D. C., Griswold, D. E., Christensen, S. B., Murdoch, R. D., Nieman, R. B., & Compton, C. H. (1999) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.1999.0181 · Cited by 156 · see citing works

1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma

Christensen, S. B., Guider, A. M., Forster, C. J., Gleason, J. G., Bender, P. E., Karpinski, J. M., DeWolf, W. E., Barnette, M. S., Underwood, D. C., Griswold, D. E., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970090r · Cited by 150 · see citing works

Distribution and pharmacology of alpha 2-adrenoceptors in the central nervous system.

MacDonald, E., & Scheinin, M. (1995) · PubMed · Cited by 137 · see citing works

Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease

Giembycz, M. A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1361 · Cited by 135 · see citing works

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway

Robichaud, A., Savoie, C., Stamatiou, P. B., Tattersall, F. D., & Chan, C. C. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00142-8 · Cited by 131 · see citing works

Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.

Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R. S., Shelton, E. R., & Conti, M. (1995) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10513-0 · Cited by 129 · see citing works

The New Phosphodiesterase 4 Inhibitor Roflumilast Is Efficacious in Exercise‐Induced Asthma and Leads to Suppression of LPS‐Stimulated TNF‐α Ex Vivo

Timmer, W., Leclerc, V., Birraux, G., Neuhäuser, M., Hatzelmann, A., Bethke, T. D., & Wurst, W. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00912700222011328 · Cited by 126 · see citing works

Assessing the emetic potential of PDE4 inhibitors in rats

Robichaud, A., Savoie, C., Stamatiou, P. B., Lachance, N., Jolicoeur, P., Rasori, R., & Chan, C. C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704457 · Cited by 120 · see citing works

Characterization of the Rolipram-Sensitive, Cyclic AMP-Specific Phosphodiesterases: Identification and Differential Expression of Immunologically Distinct Forms in the Rat Brain

Iona, S., Cuomo, M., Bushnik, T. L., Naro, F., Sette, C., Hess, M., Shelton, E. R., & Conti, M. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.1.23 · Cited by 113 · see citing works

Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

Mizobe, T., Maghsoudi, K., Sitwala, K. V., Tianzhi, G., Ou, J. I., & Maze, M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118887 · Cited by 106 · see citing works

Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret

Robichaud, A., Tattersall, F. D., Choudhury, H., & Rodger, I. W. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00190-7 · Cited by 99 · see citing works

Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD)

Barnette, M. S. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8735-9_5 · Cited by 98 · see citing works

Emetic, central nervous system and pulmonary activities of rolipram in the dog

Heaslip, R. J., & Evans, D. Y. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00457-2 · Cited by 96 · see citing works

Conformational Difference between PDE4 Apoenzyme and Holoenzyme

Laliberté, F., Han, Y., Govindarajan, A., Giroux, A., Liu, S., Bobechko, B. P., Lario, P. I., Bartlett, A. J., Gorseth, E., Gresser, M. J., et al. (2000) · Biochemistry · doi:10.1021/bi992432w · Cited by 87 · see citing works

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold, D. E., Webb, E. F., Badger, A. M., Gorycki, P. D., Levandoski, P. A., Barnette, M. A., Grous, M., Christensen, S. B., & Torphy, T. J. (1998) · PubMed · Cited by 87 · see citing works

Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A

Fawcett, L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050585197 · Cited by 77 · see citing works

The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor‐α and leukotriene B4 in a novel human whole blood assay

Brideau, C., van Staden, C., Styhler, A., Rodger, I. W., & Chan, C. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702387 · Cited by 68 · see citing works

Inhibition of adenylate cyclase in the locus coeruleus mediates the hypnotic response to an alpha 2 agonist in the rat.

Corréa-Sales, C., Nacif-Coelho, C., Reid, K., & Maze, M. (1992) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10437-0 · Cited by 64 · see citing works

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease

Barnette, M. S., & Underwood, D. C. (2000) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-200003000-00014 · Cited by 63 · see citing works

CDP840. A prototype of a novel class of orally active anti-Inflammatory phosphodiesterase 4 inhibitors

Alexander, R. P., Warrellow, G. J., Eaton, M. A. W., Boyd, E. C., Head, J. C., Porter, J. R., Brown, J. A., Reuberson, J., Hutchinson, B., Turner, P., et al. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00202-0 · Cited by 58 · see citing works

Dissecting the Cofactor-Dependent and Independent Bindings of PDE4 Inhibitors

Liu, S., Laliberté, F., Bobechko, B. P., Bartlett, A. J., Lario, P. I., Gorseth, E., Hamme, J. D. V., Gresser, M. J., & Huang, Z. (2001) · Biochemistry · doi:10.1021/bi010096p · Cited by 57 · see citing works

Pharmacology of Injectable Anesthetics

Fish, R. E. (1997) · Elsevier eBooks · doi:10.1016/b978-012417570-9/50004-0 · Cited by 35 · see citing works

Pharmacological profile of a new potent and specific ?2-adrenoceptor antagonist, L-657,743

Pettibone, D. J., Clineschmidt, B. V., Lotti, V. J., Baldwin, J. J., Huff, J. R., Randall, W. C., Vacca, J. P., & Young, S. D. (1987) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00165801 · Cited by 29 · see citing works

In vitro PKA phosphorylation‐mediated human PDE4A4 activation

Laliberté, F., Liu, S., Gorseth, E., Bobechko, B. P., Bartlett, A. J., Lario, P. I., Gresser, M. J., & Huang, Z. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02259-7 · Cited by 24 · see citing works

Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-α formation with phosphodiesterase 4 (PDE4) selective inhibitors

Muise, E. S., Chute, I. C., Claveau, D., Masson, P., Boulet, L., Tkalec, L., Pon, D. J., Girard, Y., Frenette, R., & Mancini, J. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00903-6 · Cited by 24 · see citing works

Modulation of TNF and GM-CSF Release from Dispersed Human Nasal Polyp Cells and Human Whole Blood by Inhibitors of Different PDE Isoenzymes and Glucocorticoids

Marx, D., Tassabehji, M., Heer, S., Hüttenbrink, K. B., & Szelenyi, I. (2002) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.2001.0315 · Cited by 18 · see citing works

ChemInform Abstract: 1,4‐Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosphodiesterase 4 for the Treatment of Asthma.

Christensen, S. B., & AL., E. A. E. (1998) · ChemInform · doi:10.1002/chin.199827074 · Cited by 17 · see citing works

SB-207499

Silvestre, J. S., Graul, A., & Castañer, J. (1998) · Drugs of the Future · doi:10.1358/dof.1998.023.06.457488 · Cited by 12 · see citing works

Pharmacokinetically Governed Design of Animal Toxicity Studies of a New Antidepressant Drug

Humpel, M., Kühne, G., LEHMANN, M., & Poggel, A. (1986) · Archives of toxicology. Supplement · doi:10.1007/978-3-642-71248-7_37 · Cited by 9 · see citing works

Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

Lugnier, C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.003 · Cited by 873 · see citing works

Overview of PDEs and Their Regulation

Omori, K., & Kotera, J. (2007) · Circulation Research · doi:10.1161/01.res.0000256354.95791.f1 · Cited by 797 · see citing works

Advances in targeting cyclic nucleotide phosphodiesterases

Maurice, D. H., Ke, H., Ahmad, F., Wang, Y., Chung, J. H., & Manganiello, V. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4228 · Cited by 789 · see citing works

Keynote review: Phosphodiesterase-4 as a therapeutic target

Houslay, M. D., Schafer, P. H., & Zhang, K. Y. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03622-6 · Cited by 637 · see citing works

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases

Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580 · see citing works

Cyclic AMP-specific PDE4 Phosphodiesterases as Critical Components of Cyclic AMP Signaling

Conti, M., Richter, W., Méhats, C., Livera, G., Park, J.-Y., & Jin, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r200029200 · Cited by 482 · see citing works

Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases

Card, G. L., England, B. P., Suzuki, Y., Fong, D., Powell, B., Lee, B., Luu, C. A., Tabrizizad, M., Gillette, S., Ibrahim, P. N., et al. (2004) · Structure · doi:10.1016/j.str.2004.10.004 · Cited by 444 · see citing works

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

Schafer, P. H. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.001 · Cited by 440 · see citing works

Phosphodiesterase inhibitors

Boswell‐Smith, V., Spina, D., & Page, C. P. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706495 · Cited by 411 · see citing works

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

Burgin, A. B., Magnússon, Ó. Þ., Singh, J., Witte, P., Staker, B. L., Björnsson, J. M., Þorsteinsdóttir, M., Hrafnsdóttir, S., Hagen, T. J., Kiselyov, A. S., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1598 · Cited by 396 · see citing works

Phosphodiesterases in the CNS: targets for drug development

Menniti, F. S., Faraci, W. S., & Schmidt, C. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2058 · Cited by 391 · see citing works

PDE4 inhibitors: current status

Spina, D. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.307 · Cited by 342 · see citing works

The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases

Raker, V., Becker, C., & Steinbrink, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00123 · Cited by 321 · see citing works

Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4)

O’Donnell, J. M., & Zhang, H. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.01.003 · Cited by 307 · see citing works

Distinct Roles of PDE4 and PDE10A in the Regulation of cAMP/PKA Signaling in the Striatum

Nishi, A., Kuroiwa, M., Miller, D. B., O'Callaghan, J. P., Bateup, H. S., Shuto, T., Sotogaku, N., Fukuda, T., Heintz, N., Greengard, P., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2518-08.2008 · Cited by 286 · see citing works

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease

Rabe, K. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01218.x · Cited by 272 · see citing works

Cyclic nucleotide phosphodiesterase 3A–deficient mice as a model of female infertility

Masciarelli, S., Horner, K., Liu, C., Park, S. H., Hinckley, M. D., Hockman, S. C., Nedachi, T., Jin, C., Conti, M., & Manganiello, V. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21804 · Cited by 260 · see citing works

COPD: current therapeutic interventions and future approaches

Barnes, P. J., & Stockley, R. A. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00139104 · Cited by 259 · see citing works

Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages

Jin, S.-L. C., Lan, L., Zoudilova, M., & Conti, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1523 · Cited by 256 · see citing works

Phosphodiesterase inhibitors in airways disease

Chung, K. F. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.12.059 · Cited by 243 · see citing works

Phosphodiesterase-4D Knock-Out and RNA Interference-Mediated Knock-Down Enhance Memory and Increase Hippocampal Neurogenesis via Increased cAMP Signaling

Li, Y., Cheng, Y., Huang, Y., Conti, M., Wilson, S. P., O’Donnell, J. M., & Zhang, H. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5236-10.2011 · Cited by 233 · see citing works

Prospects for new drugs for chronic obstructive pulmonary disease

Barnes, P. J., & Hansel, T. T. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17025-6 · Cited by 189 · see citing works

Cyclic Nucleotide Phosphodiesterases: important signaling modulators and therapeutic targets

Ahmad, F., Murata, T., Shimizu, K., Degerman, E., Maurice, D. H., & Manganiello, V. (2014) · Oral Diseases · doi:10.1111/odi.12275 · Cited by 184 · see citing works

Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation

Ariga, M., Neitzert, B., Nakae, S., Mottin, G., Bertrand, C., Pruniaux, M., Jin, S.-L. C., & Conti, M. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7531 · Cited by 179 · see citing works

New molecular targets for the treatment of neutrophilic diseases

Barnes, P. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.01.015 · Cited by 177 · see citing works

Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases

Schett, G. A., Sloan, V. S., Stevens, R. M., & Schafer, P. H. (2010) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x10381432 · Cited by 172 · see citing works

Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue

Richter, W., Jin, S.-L. C., & Conti, M. (2005) · Biochemical Journal · doi:10.1042/bj20050030 · Cited by 161 · see citing works

Cyclic AMP-Specific Phosphodiesterase-4 as a Target for the Development of Antidepressant Drugs

Zhang, H. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168092 · Cited by 150 · see citing works

PDE4 as a target for cognition enhancement

Richter, W., Menniti, F. S., Zhang, H., & Conti, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.818656 · Cited by 148 · see citing works

Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases

Page, C. P., & Spina, D. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17969-3_17 · Cited by 144 · see citing works

Selective PDE inhibitors as novel treatments for respiratory diseases

Page, C. P., & Spina, D. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.016 · Cited by 143 · see citing works

GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses

Bruno, O., Fedele, E., Prickaerts, J., Parker, L. A., Canepa, E., Brullo, C., Cavallero, A., Gardella, E., Balbi, A., Domenicotti, C., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01524.x · Cited by 137 · see citing works

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

Field, S. K. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s7667 · Cited by 137 · see citing works

A high-fat diet promotes depression-like behavior in mice by suppressing hypothalamic PKA signaling

Vagena, E., Ryu, J. K., Baeza-Raja, B., Walsh, N. M., Syme, C. A., Day, J. P., Houslay, M. D., & Baillie, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0470-1 · Cited by 132 · see citing works

Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory Diseases

Wittmann, M., & Helliwell, P. (2013) · Dermatology and Therapy · doi:10.1007/s13555-013-0023-0 · Cited by 132 · see citing works

An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022

Crocetti, L., Floresta, G., Cilibrizzi, A., & Giovannoni, M. P. (2022) · Molecules · doi:10.3390/molecules27154964 · Cited by 125 · see citing works

Design, Synthesis, and Pharmacological Evaluation ofN-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors

Kümmerle, A. E., Schmitt, M., Cardozo, S. V. S., Lugnier, C., Villa, P., Lopes, A. B., Romeiro, N. C., Justiniano, H., Martins, M. A., Fraga, C. A. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300514y · Cited by 121 · see citing works

Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers

Barber, R., Baillie, G. S., Bergmann, R., Shepherd, M. C., Sepper, R., Houslay, M. D., & Heeke, G. V. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00384.2003 · Cited by 121 · see citing works

Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors

Wang, H., Peng, M.-S., Chen, Y., Geng, J., Robinson, H. H., Houslay, M. D., Cai, J., & Ke, H. (2007) · Biochemical Journal · doi:10.1042/bj20070970 · Cited by 120 · see citing works

Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease

Banner, K. H., & Press, N. J. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00170.x · Cited by 119 · see citing works

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases

Phillips, J. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00259 · Cited by 119 · see citing works

Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies

Lerner, A., & Epstein, P. M. (2005) · Biochemical Journal · doi:10.1042/bj20051368 · Cited by 114 · see citing works

The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses

Vanmierlo, T., Creemers, P., Akkerman, S., van Duinen, M. A., Sambeth, A., Vry, J. D., Uz, T., Blokland, A., & Prickaerts, J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.031 · Cited by 112 · see citing works

Discovery of selective PDE4B inhibitors

Naganuma, K., Omura, A., Maekawara, N., Saitoh, M., Ohkawa, N., Kubota, T., Nagumo, H., Kodama, T., Takemura, M., Ohtsuka, Y., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.121 · Cited by 111 · see citing works

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

Siuciak, J., McCarthy, S. A., Chapin, D., & Martin, A. N. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1014-6 · Cited by 111 · see citing works

PDE4 inhibitors as new anti-inflammatory drugs: Effects on cell trafficking and cell adhesion molecules expression

Sanz, M., Cortijo, J., & Morcillo, E. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.12.001 · Cited by 108 · see citing works

Structural basis for the design of selective phosphodiesterase 4B inhibitors

Fox, D. N. A., Burgin, A. B., & Gurney, M. E. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.12.003 · Cited by 107 · see citing works

Are phosphodiesterase 4 inhibitors just more theophylline?

Boswell‐Smith, V., Cazzola, M., & Page, C. P. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.045 · Cited by 107 · see citing works

Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders

Bhat, A., Ray, B., Mahalakshmi, A. M., Tuladhar, S., Nandakumar, D., Srinivasan, M., Essa, M. M., Chidambaram, S. B., Guillemin, G. J., & Sakharkar, M. K. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105078 · Cited by 107 · see citing works

PDE4 inhibitors: a review of current developments (2005 – 2009)

Pagès, L., Gavaldà, A., & Lehner, M. D. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903313753 · Cited by 104 · see citing works

Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma

Jin, S.-L. C., Goya, S., Nakae, S., Wang, D., Bruss, M. D., Hou, C., Umetsu, D. T., & Conti, M. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.014 · Cited by 99 · see citing works

Dual PDE 3/4 and PDE 4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases

Abbott-Banner, K., & Page, C. P. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12209 · Cited by 99 · see citing works

The Role of Phosphodiesterases in Schizophrenia

Siuciak, J. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00002 · Cited by 98 · see citing works

cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor

Fujita, M., Richards, E. M., Niciu, M. J., Ionescu, D., Zoghbi, S. S., Hong, J., Telu, S., Hines, C. S., Pike, V. W., Zarate, C. A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.171 · Cited by 96 · see citing works

The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors

Paes, D., Schepers, M., Rombaut, B., van den Hove, D., Vanmierlo, T., & Prickaerts, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000273 · Cited by 97 · see citing works

The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D

Mori, F., Pérez-Torres, S., De, R., Porzionato, A., Macchi, V., Beleta, J., Gavaldà, A., Palacios, J. M., & Mengod, G. (2010) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2010.03.004 · Cited by 91 · see citing works

PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease

Banner, K. H., & Trevethick, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.008 · Cited by 89 · see citing works

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme

Siuciak, J., Chapin, D., McCarthy, S. A., & Martin, A. N. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0727-x · Cited by 97 · see citing works

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis

Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0206-2022 · Cited by 85 · see citing works

Phosphodiesterase-4 as a potential drug target

Zhang, K. Y. J., Ibrahim, P. N., Gillette, S., & Bollag, G. E. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1283 · Cited by 85 · see citing works

Phosphodiesterase inhibitors say NO to Alzheimer's disease

Nabavi, S. M., Talarek, S., Listos, J., Nabavi, S. F., Devi, K. P., de Oliveira, M. R., Tewari, D., Argüelles, S., Mehrzadi, S., Hosseinzadeh, A., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110822 · Cited by 84 · see citing works

Phosphodiesterase 4 and its inhibitors in inflammatory diseases

Jin, S.-L. C., Lin, S., & Ding, S.-L. (2012) · Biomedical Journal · doi:10.4103/2319-4170.106152 · Cited by 84 · see citing works

Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

Knott, E. P., Assi, M., Rao, S. N. R., Ghosh, M., & Pearse, D. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040696 · Cited by 83 · see citing works

Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition

McGirr, A., Lipina, T. V., Mun, H.-S., Georgiou, J., Al-Amri, A. H., Ng, E., Zhai, D., Elliott, C., Cameron, R. T., Mullins, J. G. L., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.240 · Cited by 79 · see citing works

Advanced Research on Dopamine Signaling to Develop Drugs for the Treatment of Mental Disorders: Biochemical and Behavioral Profiles of Phosphodiesterase Inhibition in Dopaminergic Neurotransmission

Nishi, A., & Snyder, G. L. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.10r01fm · Cited by 79 · see citing works

Treating COPD with PDE 4 inhibitors.

Brown, W. M. (2007) · PubMed Central · Cited by 78 · see citing works

Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders

Gurney, M. E., Nugent, R. A., Mo, X., Sindac, J. A., Hagen, T. J., Fox, D. N. A., O’Donnell, J. M., Zhang, C., Xu, Y., Zhang, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00193 · Cited by 78 · see citing works

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in <scp>J</scp> apanese adult patients with atopic dermatitis: Results of a randomized, vehicle‐controlled, multicenter clinical trial

Furue, M., Kitahara, Y., Akama, H., Hojo, S., Hayashi, N., Nakagawa, H., & The JAPANESE E6005 Study Investigators (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12534 · Cited by 77 · see citing works

Memory enhancing effects of BPN14770, an allosteric inhibitor of phosphodiesterase-4D, in wild-type and humanized mice

Zhang, C., Xu, Y., Chowdhary, A., Fox, D. N. A., Gurney, M. E., Zhang, H., Auerbach, B. D., Salvi, R., Yang, M., Li, G., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0178-6 · Cited by 77 · see citing works

Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram

Dlaboga, D., HajjHussein, H., & O’Donnell, J. M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.04.032 · Cited by 72 · see citing works

ABCD of the phosphodiesterase family: interaction and differential activity in COPD

Halpin, D. M. G. (2008) · International Journal of COPD · doi:10.2147/copd.s1761 · Cited by 69 · see citing works

Selective Phosphodiesterase 4B Inhibitors: A Review

Azam, M. A. (2014) · Scientia Pharmaceutica · doi:10.3797/scipharm.1404-08 · Cited by 68 · see citing works

Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System

Zhang, C., Xu, Y., Zhang, H., Gurney, M. E., & O’Donnell, J. M. (2017) · Scientific Reports · doi:10.1038/srep40115 · Cited by 68 · see citing works

An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease

Giembycz, M. A. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02640.x · Cited by 68 · see citing works

Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice

Guo, J., Lin, P., Zhao, X., Zhang, J., Wei, X., Wang, Q., & Wang, C. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.008 · Cited by 67 · see citing works

Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

Page, C. P. (2014) · International Archives of Allergy and Immunology · doi:10.1159/000368800 · Cited by 66 · see citing works

Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode

Kranz, M., Wall, M., Evans, B., Miah, A. H., Ballantine, S. P., Delves, C. J., Dombroski, B., Gross, J. W., Schneck, J. L., Villa, J. P., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.03.061 · Cited by 66 · see citing works

Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis

Rogliani, P., Calzetta, L., Cazzola, M., & Matera, M. G. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1199683 · Cited by 66 · see citing works

Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents

Schmidt, C. J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790411009 · Cited by 64 · see citing works

Preferential inhibition of human phosphodiesterase 4 by ibudilast

Huang, Z., Liu, S., Zhang, L., Salem, M., Greig, G. M., Chan, C., Natsumeda, Y., & Noguchi, K. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.10.026 · Cited by 63 · see citing works

Effect of Phosphodiesterase 7 (PDE7) Inhibitors in Experimental Autoimmune Encephalomyelitis Mice. Discovery of a New Chemically Diverse Family of Compounds

Redondo, M., Brea, J. M., Pérez, D. I., Soteras, I., Val, C., Pérez, C., Morales-Garcia, J. A., Alonso‐Gil, S., Paúl-Fernández, N., Martin-Alvarez, R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201720d · Cited by 61 · see citing works

2 PDE4 Inhibitors – A Review of the Current Field

Press, N. J., & Banner, K. H. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(08)00202-6 · Cited by 60 · see citing works

Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior

Hansen, R., Conti, M., & Zhang, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3480-y · Cited by 59 · see citing works

A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice

Fortin, M., Danjou, H., Higgins, M., Gougeon, J., Aubé, P., Moktefi, K., Mouissi, S., Séguin, S., Seguin, R. M., RENZI, P. M., et al. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-39 · Cited by 59 · see citing works

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine‐induced proliferation and myofibroblast conversion

Selige, J., Hatzelmann, A., & Dunkern, T. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22529 · Cited by 56 · see citing works

Treatment of Chronic Obstructive Pulmonary Disease with Roflumilast, a New Phosphodiesterase 4 Inhibitor

Gross, N. J., Giembycz, M. A., & Rennard, S. I. (2010) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412551003758304 · Cited by 56 · see citing works

The cyclic AMP phenotype of fragile X and autism

Kelley, D. J., Bhattacharyya, A., Lahvis, G. P., YIN, J., Malter, J. S., & Davidson, R. J. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.06.005 · Cited by 56 · see citing works

Novel signal transduction modulators for the treatment of airway diseases

Barnes, P. J. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.001 · Cited by 55 · see citing works

Putting the lid on phosphodiesterase 4

Houslay, M. D., & Adams, D. R. (2010) · Nature Biotechnology · doi:10.1038/nbt0110-38 · Cited by 54 · see citing works

Phosphodiesterase-4 inhibitors as a novel approach for the treatment of respiratory disease: cilomilast

Kroegel, C., & Foerster, M. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.109 · Cited by 54 · see citing works

CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window

Villetti, G., Carnini, C., Battipaglia, L., Preynat, L., Bolzoni, P. T., Bassani, F., Caruso, P. L., Bergamaschi, M., Pisano, A. R., Puviani, V., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.220558 · Cited by 52 · see citing works

RNA interference‐mediated phosphodiesterase 4D splice variants knock‐down in the prefrontal cortex produces antidepressant‐like and cognition‐enhancing effects

Wang, Z., Zhang, Y., Liu, Y., Zhao, N., Zhang, Y., Li, Y., An, L., Li, J., Wang, X., Qin, J., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02225.x · Cited by 51 · see citing works

Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice

Wang, Z., Yang, W., Zhang, Y., Zhao, N., Zhang, Y., Liu, Y., Xu, Y., Wilson, S. P., O’Donnell, J. M., Zhang, H., et al. (2015) · Scientific Reports · doi:10.1038/srep11332 · Cited by 51 · see citing works

Intracellular Targeting of Phosphodiesterase‐4 Underpins Compartmentalized cAMP Signaling

Lynch, M. J., Hill, E. V., & Houslay, M. D. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75007-4 · Cited by 50 · see citing works

PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells

Reininger, D., Fundel‐Clemens, K., Mayr, C. H., Wollin, L., Laemmle, B., Quast, K., Nickolaus, P., & Herrmann, F. E. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17303 · Cited by 48 · see citing works

Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy

Punit K Srivastava, Dastidar, S. G., & Ray, A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.7.1069 · Cited by 48 · see citing works

Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis

Abdulrahim, H., Thistleton, S., Adebajo, A., Shaw, T., Edwards, C. J., & Wells, A. F. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1034107 · Cited by 47 · see citing works

Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

Armani, E., Amari, G., Rizzi, A., Fanti, R. D., Ghidini, E., Capaldi, C., Carzaniga, L., Caruso, P. L., Guala, M., Peretto, I., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401549m · Cited by 47 · see citing works

Imidazo[1,2-b]pyridazine as privileged scaffold in medicinal chemistry: An extensive review

Garrido, A., Vera, G., Delaye, P., & Enguehard‐Gueiffier, C. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113867 · Cited by 47 · see citing works

Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease

Soto, F. J., & Hanania, N. A. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mcp.0000151715.58124.9e · Cited by 47 · see citing works

Assessing the emetic potential of PDE4 inhibitors in rats

Robichaud, A., Savoie, C., Stamatiou, P. B., Lachance, N., Jolicoeur, P., Rasori, R., & Chan, C. C. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704457 · Cited by 120 · see citing works

PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway

Robichaud, A., Savoie, C., Stamatiou, P. B., Tattersall, F. D., & Chan, C. C. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00142-8 · Cited by 131 · see citing works

Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1–5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia

Yu, M.-C., Chen, J.-H., Lai, C.-Y., Han, C.-Y., & Ko, W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.10.031 · Cited by 39 · see citing works

Antidepressant-like Profile and Reduced Sensitivity to Rolipram in Mice Deficient in the PDE4D Phosphodiesterase Enzyme

Zhang, H. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00344-5 · Cited by 228 · see citing works

Assessment of PDE4 Inhibitor-Induced Hypothermia as a Correlate of Nausea in Mice

Boyd, A., Aragon, I. V., Rich, J., McDonough, W., Oditt, M., Irelan, D. W., Fiedler, E., Saleh, L. A., & Richter, W. (2021) · Biology · doi:10.3390/biology10121355 · Cited by 10 · see citing works